Literature DB >> 9711985

Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients.

M Lanfredini1, P Fiorina, M G Peca, A Veronelli, A Mello, E Astorri, P Dall'Aglio, A Craveri.   

Abstract

The study aim was to assess the relationship between homocyst(e)inemia and microalbuminuria in non-insulin-dependent diabetes mellitus (NIDDM) patients. The study was performed on 33 NIDDM patients (16 males and 17 females), and 16 healthy control subjects (seven males and nine females). Plasma fasting and post-methionine load homocyst(e)ine (tHcy), together with other parameters that could modify tHcy levels, were assessed. There were no significant differences between NIDDM patients and controls for fasting tHcy (8.12 +/- 3.17 v 7.19 +/- 2.40 micromol/L) and post-methionine load tHcy (26.51 +/- 11.50 v 25.06 +/- 10.76 micromol/L). Moreover, there was a significant correlation between urinary albumin excretion (UAE) and fasting tHcy (r = .340, P = .05) and post-methionine load tHcy (r = .502, P = .004) in NIDDM patients. Fasting tHcy was correlated both with post-methionine load tHcy (r = .429, P = .01) and with vitamin B12 (r = -.349, P = .04) in NIDDM patients. Microalbuminuric NIDDM patients had higher fasting tHcy (9.05 +/- 3.83 micromol/L) than normoalbuminurics (7.12 +/- 1.95 micromol/L). In addition, NIDDM patients with complications presented higher fasting tHcy values than the group without complications (9.61 +/- 3.34 v 6.53 +/- 2.09 micromol/L, Kolmogorov-Smirnov two-sample test for nonparametric data [KS] = 1.794, P = .003), without any other significant differences in the parameters considered. tHcy could be an important risk factor worsening the prognosis in NIDDM patients, especially microalbuminuric patients. Microalbuminuric NIDDM patients could be particularly prone to hyperhomocyst(e)inemia, probably due to endothelial or renal dysfunction with a reduction in the scavenging of tHcy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711985     DOI: 10.1016/s0026-0495(98)90344-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Folate supplementation reduces serum hsp70 levels in patients with type 2 diabetes.

Authors:  Claire Hunter-Lavin; Peter R Hudson; Sagarika Mukherjee; Gareth K Davies; Clive P Williams; John N Harvey; David F Child; John H H Williams
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

4.  Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study.

Authors:  Franziska Marti; Peter Vollenweider; Pedro-Manuel Marques-Vidal; Vincent Mooser; Gérard Waeber; Fred Paccaud; Murielle Bochud
Journal:  BMC Public Health       Date:  2011-09-26       Impact factor: 3.295

Review 5.  The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents.

Authors:  Ida Pastore; Andrea Mario Bolla; Laura Montefusco; Maria Elena Lunati; Antonio Rossi; Emma Assi; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.